Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions

This publication has 122 references indexed in Scilit:

• A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
  PLOS ONE, 2013
• Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
  New England Journal of Medicine, 2012
• Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
  Annals of Oncology, 2009
• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
  Proceedings of the National Academy of Sciences, 2008
• Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2
  EMBO Reports, 2008
• Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
  New England Journal of Medicine, 2007
• A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
  Nature, 2007
• Prognostic markers in triple‐negative breast cancer
  Cancer, 2006
• Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer
  JAMA, 2006
• Phosphotyrosine interactome of the ErbB‐receptor kinase family
  Molecular Systems Biology, 2005